奥沙利铂联合卡培他滨术后辅助治疗回盲部癌致间质性肺炎伴CA19-9升高一例

打开文本图片集

关键词：奥沙利铂；卡培他滨；间质性肺炎；CA19-9；复发转移

中图分类号：R735.3；R453.9 文献标识码：B 文章编号：1000-503X（2025）04-0660-06

DOI：10.3881/j.issn.1000-503X.16328

Interstitial Lung Disease With CA19-9 Elevation After Oxaliplatin and Capecitabine Adjuvant Therapy for Ileocecal Carcinoma： Report of One Case

YANG Wenjing，YANG Guowang，LI Ying，WANG Hao，YANG Lin，XU Weiru

DepartmentofOncology，Beijing HospitalofTraditionalChineseMedicine，CapitalMedicalUniversity，Beijing1Oo0，China

Corresponding author：XUWeiru Tel：O1O-87906029，E-mail：xuweiru@bjzhongyi.com

ABSTRACT：Both carcinoembryonic antigen and CA19-9 are considered as predictive markers of intestinal cancer recurrence and metastasis.In addition，CA19-9 elevation is considered as a predictive markerof connective tissue disease-related interstitial lungdisease.The incidence of oxaliplatinand capecitabine-associated nterstitial lung disease is low，and there is no report about CA19-9 as apredictive marker ofoxaliplatin and capecitabine-associated interstitial lung disease.This paper reports acaseof interstitial lung disease with CA19-9 elevation caused byoxaliplatin and capecitabine adjuvant therapy for ileocecal carcinoma.The change trend of serum carcinoembryonic antigen in this patient was consistent with tumor recurrence and metastasis，and that of serum CA19-9 was consistent with the severity of interstitial lung disease.Therefore，CA19-9 elevation after intestinal cancer surgery does not necessarily indicate the tumor recurrence and metastasis，and atention should be paid to the possibility of oxaliplatin and capecitabine-associated interstitial lung disease.

KeyWords：oxaliplatin；capecitabine；interstitial lung disease；CA19-9；recurrence and metastasis

ActaAcadMedSin，2025，47（4）：660-665

癌胚抗原（carcinoembryonicantigen，CEA）是监测肠癌术后复发转移常用标志物，指南推荐术前及术后每3～6个月进行CEA检测[1-2]。（剩余12760字）